Abstract
The management of patients with acute myocardial infarction has changed dramatically in the past decade. These changes have resulted in marked reductions in mortality and improved quality of life. The major advance has been reperfusion therapy with either intravenous thrombolysis or direct percutaneous transluminal coronary angioplasty. Despite the general appreciation of these treatments, they remain underused or are administered in a delayed fashion, resulting in loss of the potential benefit of these powerful therapies. Issues of cost certainly play a role in some jurisdictions regarding the choice of a reperfusion strategy for an individual patient. Many adjunctive treatments have been tested as a means of maximizing the benefit of early reperfusion. Those that are of benefit include aspirin, heparin, β-blockers, and angiotensin-converting enzyme inhibitors. Those of marginal or no benefit include nitrates, magnesium, antiarrhythmic agents, and calcium-channel blockers.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
